When We Say "OX40 Inhibition," What Do We Mean? Emma Guttman-Yassky, MD, PhD, Explains
EADV 2025: Guttman-Yassky has great confidence in the future of agents that block the OX40 pathway, suggesting that they have the potential for disease modification.
Pilot Trial Challenges Routine Steroid Use After Pediatric Anaphylaxis ED Discharge
Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.
Urine-Based Cervical Cancer Screening Evaluated in World's Largest Study
The new study, based in China, will validate urine-based genetic methylation testing which concentrates trace amounts of HPV DNA by more than 10,000 times.
FDA Approves Guselkumab as First IL-23 Inhibitor With Fully Subcutaneous Induction Regimen for Ulcerative Colitis
FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.
No Rx Required for COVID-19 Vaccination But ACIP Calls for Better Informed Consent Process
The ACIP on September 19 narrowly voted against requiring a prescription to get the shot but urged more detailed discussion of vaccine risks during shared decision making conversations.
GLP-1 RAs May Reduce Risk for Cancer in Adults with Obesity: Daily Dose
Your daily dose of the clinical news you may have missed.
Cervical Cancer Screening in Primary Care: A Q&A with Family Physician Ada Stewart, MD
Explore essential insights on cervical cancer screening, patient engagement, and innovative self-collection methods this Gynecologic Cancer Awareness Month.
Elinzanetant Update: Phase 3 Findings Published in JAMA with PDUFA Date Set for October 26
If approved, the nonhormonal drug could offer an important new option for postmenopausal women seeking alternatives to hormone therapy.
FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group
Incyte announced the agency's decision, which was based on findings of significant reduction in atopic dermatitis signs and symptoms during the TRuE-AD3 clinical trial.
Physicians Attending Day 1 of ACIP Meeting Said They Need to be Heard
Discussions on day 1 focused on the difference between the MMR and MMR+V vaccines, with clinicians calling for inclusion of real-world experience in any ACIP decision.
Emma Guttman-Yassky, MD, PhD, Outlines Phase 3 SHUTTLE Program with Rocatinlimab for Atopic Dermatitis
EADV 2025: Guttman-Yassky presented data from the phase 3 ROCKET-IGNITE trial and highlights its importance in the context of the global ROCKET development program.
Vaginal Estradiol Shows No Added Risk of Repeat Stroke in Women: Daily Dose
OX40 Inhibitor Rocatinlimab Shows Significant Response in Combination with Topical Therapy for AD
EADV 2025: Phase 3 ROCKET-SHUTTLE results showed the T-cell rebalancing therapy significantly improved AD signs and symptoms in treatment-experienced adults.
Cervical Cancer Screening in Primary Care: Family Physician Ada Stewart, MD, on Guidelines, Patient Hesitancy, and HPV Self-Collection
Ada Stewart, MD, reviews current guidelines, addresses patient hesitancy, and explains how HPV self-collection tests may expand screening options in primary care.
Temtokibart Shows Efficacy and Strong Biomarker Response in Phase 2b Trial for Atopic Dermatitis
The novel IL-22 blocker was associated with improvements in EASI as early as week 1 for lower doses and week 2 for the highest dose, compared with placebo.
Phase 3 Data Support Efficacy of Delgocitinib Cream in Adolescents With Chronic Hand Eczema; Pooled Analysis Confirms Safety in Adults
EADV 2025: New phase 3 data reveal delgocitinib cream's efficacy for chronic hand eczema in adolescents, confirming its safety profile in adults.
FDA Updates Albuterol/Budesonide Label to Include Evidence of Exacerbation Risk Reduction in Mild Asthma
The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.
Tirzepatide Lowers A1C and BMI in Children and Adolescents with Type 2 Diabetes
In children aged 10 to <18 with T2D inadequately controlled on standard of care treatment, tirzepatide reduced HbA1c by an average of 2.2% and reduced BMI as well.
Nontraditional Causes of MI Found Common in Younger Adults, Especially in Women
Atypical causes of MI in women included spontaneous coronary artery dissection, which was 6 times more common in women than in men, a Mayo Clinic study found.
The ACIP Meets on September 18 as Vaccine Policy Hangs in the Balance
Regardless of decisions made during the ACIP meeting, health insurance plans will continue to cover shots recommended by ACIP as of Sept 1.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "When We Say \"OX40 Inhibition,\" What Do We Mean? Emma Guttman-Yassky, MD, PhD, Explains")
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Cervical Cancer Screening in Primary Care: A Q&A with Family Physician Ada Stewart, MD")
